10185-00-9

Basic information

• Product Name: delta(3)-chromene-3-carboxamide
• Synonyms: delta(3)-chromene-3-carboxamide;2H-1-Benzopyran-3-carboxamide;69-20;Compound 69/20;2H-ChroMene-3-carboxaMide
• CAS NO: 10185-00-9
• Molecular Formula: C₁₀H₉NO₂
• Molecular Weight: 175.18
• Mol File: 10185-00-9.mol
• Article Data: 1

Chemical Properties

• Melting Point: 149-151 °C
• Boiling Point: 413.5°Cat760mmHg
• Flash Point: 253°C
• Appearance: /
• Density: 1.278g/cm³
• Vapor Pressure: 4.76E-07mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: 2-8°C
• PKA: 15.11±0.20(Predicted)
• CAS DataBase Reference: delta(3)-chromene-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: delta(3)-chromene-3-carboxamide(10185-00-9)
• EPA Substance Registry System: delta(3)-chromene-3-carboxamide(10185-00-9)

Safety Data

• Hazardous Substances Data: 10185-00-9(Hazardous Substances Data)

Usage

Description

Delta(3)-chromene-3-carboxamide, also known as Lemborexant, is a chemical compound that functions as a potent dual orexin receptor antagonist. It is specifically designed to treat insomnia by targeting the orexin system in the brain, which is integral to the regulation of wakefulness and sleep-wake cycles. By inhibiting the binding of orexin to its receptors, Lemborexant facilitates sleep onset and maintenance, thereby enhancing sleep quality for those who struggle with insomnia.

Uses

Used in Pharmaceutical Industry:
Delta(3)-chromene-3-carboxamide is utilized as a sleep aid for individuals experiencing difficulty in falling asleep or maintaining sleep. It is particularly effective for those with insomnia, as it targets the orexin receptors in the brain, which are key regulators of the sleep-wake cycle. This targeted approach allows for a more focused treatment of sleep disorders, leading to improved sleep quality and overall well-being.
delta(3)-chromene-3-carboxamide has been approved for use in the United States and several other countries, and is available in tablet form for oral consumption. It is generally well-tolerated, with common side effects such as headache, somnolence, and dizziness, which are typically manageable and do not outweigh the benefits of improved sleep for those who require this medication.

InChI:InChI=1/C10H9NO2/c11-10(12)8-5-7-3-1-2-4-9(7)13-6-8/h1-5H,6H2,(H2,11,12)

Upstream product

• 90-02-8 salicylaldehyde 
• 107-13-1 acrylonitrile 

Downstream Products

• 83823-46-5 1-Chroman-3-ylmethyl-4-(2-methoxy-phenyl)-piperazine; hydrochloride 
• 83823-38-5 (2H-Chromen-3-ylmethyl)-phenethyl-amine; hydrochloride 
• 83823-39-6 (2H-Chromen-3-ylmethyl)-diethyl-amine; hydrochloride 
• 83823-27-2 (2H-Chromen-3-yl)-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone 
• 83823-35-2 1-(2H-Chromen-3-ylmethyl)-4-(2-methoxy-phenyl)-piperazine 
• 83823-09-0 (2H-Chromen-3-yl)-(4-phenyl-piperazin-1-yl)-methanone 
• 83823-37-4 1-(2H-Chromen-3-ylmethyl)-4-phenyl-piperazine 
• 83823-44-3 1-Chroman-3-ylmethyl-4-phenyl-piperazine 
• 83823-15-8 2H-Chromene-3-carboxylic acid (2-hydroxy-2-phenyl-ethyl)-amide 
• 83823-10-3 2H-Chromene-3-carboxylic acid phenethyl-amide 
• 83823-26-1 (2H-Chromen-3-yl)-(4-methyl-piperazin-1-yl)-methanone 
• 83823-11-4 2H-Chromene-3-carboxylic acid pyridin-3-ylamide 
• 83823-16-9 2H-Chromene-3-carboxylic acid (2-diethylamino-ethyl)-amide 
• 83823-12-5 (2H-Chromen-3-yl)-(2-imino-2H-pyridin-1-yl)-methanone 

Relevant articles and documents

Chromene and Chroman 3-Carboxamides and Some Related Compounds as a New Class of Centrally Acting Agents

A number of chromene-3-carboxamides (7), 3-Aminochromans (11) and 3-aminomethylchromans (9) have been synthesized.Chromene-3-carboxamides have been found to exhibit strong central muscle relaxant activity compared to mephesin.